Search clinical trials for: 90Y-hPAM4 gemcitabine

Total 3856 results

University of Pittsburgh
National Cancer Institute (NCI)

Withdrawn

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

Bladder Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Malignant Mesothelioma

United States
AmpliMed Corporation

Completed

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Eli Lilly and Company

Completed

Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer

Non-Small Cell Lung Cancer

China
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary

Carcinoma

France
Eli Lilly and Company

Completed

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Carcinoma, Non-Small-Cell Lung

Russian Federation
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
ANRS, Emerging Infectious Diseases
INSERM SC10-US19

Recruiting

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

HIV-1-infection, Subtype b

Belgium, France
RenJi Hospital

Recruiting

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Zhejiang University

Completed

S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer

Pancreatic Cancer

China
Gachon University Gil Medical Center

Completed

A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.

Advanced Colorectal Cancer

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia

Leukemia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Eli Lilly and Company

Completed

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

Metastatic Breast Cancer

Japan
Korea University Anam Hospital
Seoul National University Hospital; Seoul National University Bundang Hospital and other collaborators

Completed

A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer

Neoplasm Metastasis | Pancreatic Neoplasm

Korea, Republic of
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Taiho Oncology, Inc.

Recruiting

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Institute of Liver and Biliary Sciences, India

Recruiting

Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.

Decompensated Cirrhosis

India
Seoul National University Hospital

Unknown

Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study

Epilepsy

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

BMS-986253 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Fujifilm Pharmaceuticals U.S.A., Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Advanced Solid Tumor

United States
Novartis Pharmaceuticals

Completed

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Pancreatic Cancer

Spain, United Kingdom, United States
National Cancer Institute, Naples
Gruppo Oncologico Italia Meridionale; Gruppo Italiano per lo studio dei Carcinomi... and other collaborators

Terminated

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients (CAPPA-2)

Non-Small Cell Lung Cancer

Italy
Swiss Group for Clinical Cancer Research

Completed

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Lymphoma

Switzerland
Ulsan University Hospital
Jeil Pharmaceutical Co., Ltd.

Unknown

Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Eli Lilly and Company

Completed

Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes

Metastatic Breast Cancer

Saudi Arabia
Universidade do Porto
Ludwig-Maximilians - University of Munich; Fundação para a Ciência e a Tecnologia and other collaborators

Recruiting

Influence of Posture and Positioning in Rescuer's Fatigue and Quality of Chest Compressions (QualityCPR)

Cardiopulmonary Resuscitation

Portugal
Reata, a wholly owned subsidiary of Biogen

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults

Healthy

United States
Pfizer

Completed

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Overactive Bladder

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Pfizer

Completed

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Zhang Xiaofeng,MD
College of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute...

Not yet recruiting

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Pancreatic Cancer

China
iOnctura

Recruiting

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Italy, United Kingdom
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Bladder Cancer

United States
Peking Union Medical College Hospital
National Natural Science Foundation of China

Unknown

Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy

Inflammation | Pancreatic Neoplasms

China
Roswell Park Cancer Institute
Abbott

Completed

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Vion Pharmaceuticals

Completed

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States, Netherlands
Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Australia, Singapore, Hong Kong, Korea, Republic of
Gachon University Gil Medical Center

Completed

A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of
Xian-Janssen Pharmaceutical Ltd.

Completed

An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

China
Chunguang yang (101937)

Recruiting

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Urothelial Carcinoma | Radical Cystectomy

China

Search clinical trials for: 90Y-hPAM4 gemcitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations